Bristol-Myers Squibb (BMS), an American pharmaceutical company, has obtained a registration certificate from the Ministry of Health of the Russian Federation for their drug “Inrebik” (fedratinib). This medication is designed to treat myelofibrosis, a rare medical condition that results in the replacement of bone marrow with scar tissue.
Fedratinib is highly effective in combatting the symptoms of primary and secondary myelofibrosis, including splenomegaly, which is the enlargement of the spleen. Inrebik comes in capsule form with a strength of 100 mg.
The drug was approved in 2019 in the US, making it the second option for myelofibrosis patients, in addition to Jakafi by Novartis. Clinical studies on 289 patients have shown that Inrebika produced a significant therapeutic effect on 35 out of 96 individuals who underwent MRI or CT scans. Thirty-six patients experienced a reduction in the frequency of symptoms of at least 50%.
